Do you have to stay on Wegovy for life — and what happens if you stop?

Picture yourself six months in: things are going well, but you wonder how long this lasts

You have lost a meaningful amount of weight. The nausea from the early weeks is a memory. Life feels lighter. Then the question arrives, usually quietly: do I have to keep injecting forever?

It is one of the most common things people ask, and the honest answer starts with the biology. Semaglutide works by activating GLP-1 receptors that signal fullness and slow gastric emptying. While it is in your system, appetite is genuinely reduced. When it leaves (which happens within weeks of stopping) those receptors return to baseline. Hunger comes back, not because willpower failed, but because the physiological brake has been released.

The STEP 1 trial, published in the New England Journal of Medicine, followed adults who had completed 68 weeks on semaglutide 2.4mg. Participants who then stopped the medicine and continued lifestyle support regained an average of about two-thirds of their lost weight over the following 12 months. That figure is striking, and it is important context for anyone making this decision. It does not mean everyone regains all of it, but the pattern is consistent and well-documented.

For a broader picture of how semaglutide works and what the UK licensing covers, the semaglutide treatment overview on this site explains both in plain terms.

Who does stop Wegovy, and what tends to go right for them

Not everyone who stops regains everything. Some people do step down successfully, particularly when treatment has coincided with real, embedded changes to how they eat and move. The medicine gave them the appetite reduction they needed to break old patterns; those patterns (smaller portions, less ultra-processed food, regular walking) became habit rather than effort. When the medicine stopped, the habit held.

That outcome is genuinely possible. It is also not guaranteed, and it is harder to predict in advance than most people hope. Factors that tend to matter include how long treatment lasted, how much weight was lost, whether a weight-related condition (such as high blood pressure or sleep apnoea) has resolved, and whether lifestyle changes feel sustainable without the appetite suppression the medicine provided.

NICE's guidance on semaglutide for weight management, set out in NICE technology appraisal TA875, notes that treatment should be reviewed if weight loss is less than five percent after six months at the maintenance dose, a reminder that stopping is already built into the clinical framework when the medicine is not working as hoped. The flip side is that continuing when it is working is equally a legitimate clinical choice.

If you are weighing the longer-term picture for your own situation, it helps to understand whether you actually have to stay on Wegovy, which covers some of the same ground from a slightly different angle.

Pausing versus stopping, and why the distinction matters

There is a practical difference between pausing treatment and stopping it. People pause for all kinds of reasons: surgery, pregnancy, a planned holiday where the cold chain is not guaranteed, or simply a month where the finances do not stretch. Pausing is not the same as deciding treatment is finished. Coming back after a short break usually means restarting at a lower dose so the body readjusts, and that is something to plan with a prescriber rather than guess at.

Many people find it useful to read about whether staying on Wegovy forever is really what long-term treatment means, since the reality is more nuanced than a simple yes or no. That might be the right call. It might also benefit from a taper or a longer review period before the decision is final, again, a clinical conversation rather than one to make on a quiet Tuesday evening. It is worth noting that repeat orders through a regulated service like Wegovy at nume are individually reviewed each time, so any shift in your situation is picked up before the next supply is approved.

Timing matters too, in ways that are easy to overlook. A patient who pauses in December because of Christmas spending and plans to restart in January has a very different situation to someone who has been stable at maintenance dose for a year and is ready to try life without the medicine. Our prescribers see both, and the right response to each is different. If you have questions about your specific circumstances, the support team is available seven days a week.

Making the decision with a prescriber, not instead of one

The question of duration is live in clinical practice. Obesity is increasingly understood as a chronic condition, not a temporary one, which shifts how prescribers think about medicines that treat it. Some people will need long-term support, in the same way someone with high blood pressure might stay on antihypertensives for many years. Others will reach a stable point and step down with a plan. There is no universal right answer.

What there is, is a structured way to think it through. A prescriber can look at your weight trajectory, your current dose, any comorbidities that are being managed through weight loss, and how you feel about continuing. That conversation is worth having before anything changes. If you want to understand what the evidence says about indefinite use, our page on whether you can stay on Wegovy for life sets out what is currently known in plain terms, or read through how treatment decisions work more generally on the weight-loss treatment overview.

If you are not yet on treatment but are thinking about whether starting is worth it given the long-term picture, that is actually a very sensible question to bring to a consultation. Starting your free consultation with our prescribers is the right first step, not to be sold anything, but to have the honest conversation this question deserves.

Start your free consultation at our treatment page, where a GPhC-registered prescriber reviews your case the same day, not software.